The companies plan to use machine learning and simulation to study disease drivers and identify existing and new therapies, focusing first on cardiovascular disease.
Researchers identified rises and declines in disease risk that appeared to coincide with the proportion of ancestry from Mapuche and Aymara populations.
A curation working group established a framework that considers the nature and strength of the available evidence when evaluating gene-disease associations.
Separate studies in NEJM from Regeneron Pharmaceuticals and Ionis Pharmaceuticals target the ANGPTL3 gene in an effort to develop heart disease treatments.
Looking at 927 patients undergoing coronary angiography, the researchers identified a four-protein panel that outperformed traditional clinical measures.
The company, still collecting utility data, anticipates that this more complex analysis will lead to better personalization of health and wellness strategies for its clients.
The researchers believe that by monitoring mtDNA copy number in blood, they will be able to identify people at risk for developing CHD who could benefit from preventative efforts.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
